Business
Primary Endpoint Successfully Achieved in Lexaria's Phase 1b Study GLP-1-H24-4
DehydraTECH-semaglutide reduced overall side effects by 48% as compared to Rybelsus® DehydraTECH-semaglutide reduced gastrointestinal side effects by 55% as compared to Rybelsus® Recent financings create runway for prospective new 2026 development ...
About this update from Lexaria Bioscience Corp.
[{"type":"list","items":[{"val":[{"type":"text","content":"DehydraTECH-semaglutide reduced overall side effects by 48% as compared to Rybelsus®","length":92,"tagName":"p"}]},{"val":[{"type":"text","content":"DehydraTECH-semaglutide reduced gastrointestinal side effects by 55% as compared to Rybelsus®","length":101,"tagName":"p"}]},{"val":[{"type":"text","content":"Recent financings create runway for prospective new 2026 development opportunities","length":82,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":275,"olType":false},{"type":"text","content":"KELOWNA, BC / ACCESS Newswire / December 23, 2025 / Lexaria Bioscience Corp. (Nasdaq:LEXX)(Nasdaq:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, provides the following final primary and major secondary efficacy endpoint results update on its Phase 1b, 12-week chronic study GLP-1-H24-4 (the " Study " or the " Lexaria Study "), recently completed in Australia, focusing on 4 DehydraTECH ® ( "DHT" ) study arms relative to the Rybelsus® control study arm.","length":541,"tagName":"p"},{"type":"text","content":""We are extremely pleased to not only have successfully achieved our primary endpoint," stated Richard Christopher, CEO of Lexaria, "but to have also demonstrated obvious superiority in reducing unwanted side effects by as much as approximately half as compared to the world's only approved oral-based GLP-1 medication, Rybelsus ® . The receipt of the results allows us to now relay the dataset to our Material Transfer Agreement partner."","length":463,"tagName":"p"},{"type":"text","content":""The final study results follow our recent financing activities," Mr. Christopher continued. "We are thrilled to have opportunistically raised a gross total of $7.5 million over two transactions, each at share price high points at the time, since our fiscal year-ended on August 31, 2025. As previously reported, we had limited resources remaining ($1.8 million in cash on hand as of August 31, 2025) which hindered our ability and runway to proceed forward with our DehydraTECH research and partnering efforts. The financings allow us to fund prospective new development opportunities for the entirety of calendar 2026, the details of which are in the process of being finalized...